<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Meuleman, E.J.</title>
    <link>http://repub.eur.nl/res/aut/9456/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Cost utility analysis of sildenafil compared with papaverine-phentolamine injections (Article)</title>
      <link>http://repub.eur.nl/res/pub/9356/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: To compare the cost effectiveness of sildenafil and
          papaverine-phentolamine injections for treating erectile dysfunction.
          DESIGN: Cost utility analysis comparing treatment with sildenafil
          (allowing a switch to injection therapy) and treatment with
          papaverine-phentolamine (no switch allowed). Costs and effects were
          estimated from the societal perspective. Using time trade-off, a sample of
          the general public (n=169) valued health states relating to erectile
          dysfunction. These values were used to estimated health related quality of
          life by converting the clinical outcomes of a trial into quality adjusted
          life years (QALYs). PARTICIPANTS: 169 residents of Rotterdam. MAIN OUTCOME
          MEASURES: Cost per quality adjusted life year. RESULTS: Participants
          thought that erectile dysfunction limits quality of life considerably: the
          mean utility gain attributable to sildenafil is 0.11. Overall, treatment
          with sildenafil gained more QALYs, but the total costs were higher. The
          incremental cost effectiveness ratio for the introduction of sildenafil
          was pound sterling 3639 in the first year and fell in following years.
          Doubling the frequency of use of sildenafil almost doubled the cost per
          additional QALY. CONCLUSIONS: Treatment with sildenafil is cost effective.
          When considering funding sildenafil, healthcare systems should take into
          account that the frequency of use affects cost effectiveness.</description>
    </item> <item>
      <title>Transurethral deroofing of midline prostatic cyst for subfertile men (Article)</title>
      <link>http://repub.eur.nl/res/pub/9156/</link>
      <pubDate>1999-01-01T00:00:00Z</pubDate>
      <description>We evaluated the efficacy of transurethral deroofing of a midline
          prostatic cyst in subfertile men with one or more of the following semen
          abnormalities: decreased ejaculatory volume, decreased sperm motility and
          oligo- or azoospermia. Results from treatment of a series of 11 subfertile
          men with a midline prostatic cyst by transurethral deroofing of the cyst
          are presented. Five patients showed an improvement of seminal volume. Only
          one patient demonstrated an improvement of sperm count. Sperm motility was
          not influenced. No relationship was found between positive outcome
          following operation and either size of the cyst or dilatation of the
          seminal vesicles. Spontaneous pregnancies did not occur after
          transurethral deroofing of the midline prostatic cyst. In conclusion, our
          study suggests a poor efficacy of transurethral deroofing of a midline
          prostatic cyst in subfertile men with the above mentioned semen
          abnormalities.</description>
    </item>
  </channel>
</rss>